The outlook of companies tied to Viagra's history presents a complex investment picture . While the initial surge generated substantial gains, generic alternatives have significantly diminished market share . Investing in connected pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving patient trends , and